<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000641130"><TermName>mapatumumab</TermName><TermPronunciation>(ma-puh-TOO-moo-mab)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of some types of cancer. It binds to a protein called TRAIL R1 on the surface of some tumor cells.  This may kill the tumor cells. Mapatumumab is a type of monoclonal antibody. Also called anti-TRAIL R1-mAb and HGS-ETR1.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000722514" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;mapatumumab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000722513" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;mapatumumab&quot;" language="es" id="_4"/><SpanishTermName>mapatumumab</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento de ciertos tipos de cáncer. Se une a una proteína de la superficie de algunas células tumorales que se llama TRAIL R1. Podría destruir células tumorales. El mapatumumab es un tipo de anticuerpo monoclonal. También se llama anti-TRAIL R1-mAbmAb anti TRAIL R1 y HGS-ETR1.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2009-05-19</DateFirstPublished></GlossaryTerm>
